Login to Your Account

Other News To Note

Wednesday, July 25, 2012
• Celgene International Sarl, of Boudry, Switzerland, a subsidiary of Celgene Corp., said it will request a re-examination of the negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Istodax (romidepsin) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription